These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 22111754)

  • 1. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial.
    Chiong JR; Kim S; Lin J; Christian R; Dasta JF
    J Med Econ; 2012; 15(2):276-84. PubMed ID: 22111754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
    Dasta JF; Chiong JR; Christian R; Lin J
    Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of tolvaptan treatment vs. fluid restriction based on real-world data among hospitalized patients with heart failure and hyponatremia.
    Dasta JF; Sundar S; Chase S; Lingohr-Smith M; Lin J
    Hosp Pract (1995); 2018 Oct; 46(4):197-202. PubMed ID: 30045645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
    Cyr PL; Slawsky KA; Olchanski N; Krasa HB; Goss TF; Zimmer C; Hauptman PJ
    Am J Health Syst Pharm; 2011 Feb; 68(4):328-33. PubMed ID: 21289328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resource utilization in patients hospitalized with heart failure: insights from a contemporary national hospital database.
    Hauptman PJ; Swindle J; Burroughs TE; Schnitzler MA
    Am Heart J; 2008 Jun; 155(6):978-985.e1. PubMed ID: 18513507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource burden associated with hyponatremia among patients hospitalized for heart failure in the US.
    Amin A; Deitelzweig S; Christian R; Friend K; Lin J; Lowe TJ
    J Med Econ; 2013; 16(3):415-20. PubMed ID: 23336297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia.
    Amin AN; Ortendahl JD; Harmon AL; Kamat SA; Stellhorn RA; Chase SL; Sundar SV
    Curr Med Res Opin; 2018 Mar; 34(3):559-566. PubMed ID: 29297709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US.
    Amin A; Deitelzweig S; Christian R; Friend K; Lin J; Belk K; Baumer D; Lowe TJ
    J Hosp Med; 2012 Oct; 7(8):634-9. PubMed ID: 22961813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyponatremia-associated healthcare burden among US patients hospitalized for cirrhosis.
    Deitelzweig S; Amin A; Christian R; Friend K; Lin J; Lowe TJ
    Adv Ther; 2013 Jan; 30(1):71-80. PubMed ID: 23292659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
    de Lissovoy G; Fraeman K; Teerlink JR; Mullahy J; Salon J; Sterz R; Durtschi A; Padley RJ
    Eur J Health Econ; 2010 Apr; 11(2):185-93. PubMed ID: 19582491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
    Hauptman PJ; Burnett J; Gheorghiade M; Grinfeld L; Konstam MA; Kostic D; Krasa HB; Maggioni A; Ouyang J; Swedberg K; Zannad F; Zimmer C; Udelson JE;
    J Card Fail; 2013 Jun; 19(6):390-7. PubMed ID: 23743487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National trends and determinants of hospitalization costs and lengths-of-stay for uterine fibroids procedures.
    Becker ER
    J Health Care Finance; 2007; 33(3):1-16. PubMed ID: 19175228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
    Blair JE; Zannad F; Konstam MA; Cook T; Traver B; Burnett JC; Grinfeld L; Krasa H; Maggioni AP; Orlandi C; Swedberg K; Udelson JE; Zimmer C; Gheorghiade M;
    J Am Coll Cardiol; 2008 Nov; 52(20):1640-8. PubMed ID: 18992654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care utilization, costs, and readmission rates associated with hyponatremia.
    Deitelzweig S; Amin A; Christian R; Friend K; Lin J; Lowe TJ
    Hosp Pract (1995); 2013 Feb; 41(1):89-95. PubMed ID: 23466971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
    Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
    Cavalcante JL; Khan S; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1331-8. PubMed ID: 19018685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.